--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About ERAS20260717C5
Biological Technology
Erasca, Inc., was incorporated in Delaware on July 2, 2018. The company is a clinical-stage precision oncology company focused on discovering, developing and commercializing therapies for cancer patients driven by the RAS/MAPK pathway. Co-founded by leading pioneers in precision oncology and RAS targeting, the company aims to create new therapies and combination programs aimed at completely shutting down the RAS/MAPK pathway to treat cancer.
